Status:
COMPLETED
ACT-128800 in Psoriasis
Lead Sponsor:
Actelion
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.
Eligibility Criteria
Inclusion
- Adult males and females with moderate to severe plaque psoriasis who require systemic treatment and for whom participation in a placebo-controlled study of an investigational drug is justified.
Exclusion
- Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis.
- Systemic or topical treatments for psoriasis other than emollients.
- Ongoing bacterial, viral or fungal infections.
- History or presence of malignancy.
- Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00852670
Start Date
October 1 2008
End Date
September 1 2009
Last Update
November 13 2009
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Landeskrankenhaus - Universitätsklilnikum Graz, Allgemeine Dermatologie
Graz, Austria, 8036
2
University Klinik of Vienna
Vienna, Austria, 1090
3
Departement de Pneumologie/ Unité Immunologie Clinique Allergie- Centre Hospitalier Lyon sud
Lyon, France, 69000
4
CHU de Nice-Hôpital de l'Archet 2 / Service de dermatologie
Nice, France, 6202